Does the media refer more to ELDN or BTMD?

In the previous week, biote had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 3 mentions for biote and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.23 beat biote's score of 0.38 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive biote 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, TKNO or BTMD?

biote has higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Teknova $40.52M 7.18 -$17.26M -$0.32 N/A biote $192.22M 0.46 $27.05M $0.44 5.36

Is TKNO or BTMD more profitable?

biote has a net margin of 8.29% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets Alpha Teknova -41.07% -24.32% -16.34% biote 8.29% -25.72% 15.12%

Which has higher valuation and earnings, HUMA or BTMD?

biote has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.04M 162.16 -$40.83M -$0.57 N/A biote $192.22M 0.46 $27.05M $0.44 5.36

Is HUMA or BTMD more profitable?

biote has a net margin of 8.29% compared to Humacyte's net margin of -4,836.06%. biote's return on equity of -25.72% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% biote 8.29% -25.72% 15.12%

Does the media favor HUMA or BTMD?

In the previous week, biote had 1 more articles in the media than Humacyte. MarketBeat recorded 3 mentions for biote and 2 mentions for Humacyte. Humacyte's average media sentiment score of 1.04 beat biote's score of 0.38 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive biote 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ZNTL or BTMD?

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 3 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 0.47 beat biote's score of 0.38 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral biote 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BTMD or AVXL more profitable?

biote has a net margin of 8.29% compared to Anavex Life Sciences' net margin of 0.00%. biote's return on equity of -25.72% beat Anavex Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets biote 8.29% -25.72% 15.12% Anavex Life Sciences N/A -38.76% -35.01%

Does the media prefer BTMD or AVXL?

In the previous week, biote had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for biote and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.93 beat biote's score of 0.38 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

biote (BTMD) Competitors

$2.36 +0.25 (+11.85%)

Closing price 04:00 PM Eastern

Extended Trading

$2.38 +0.02 (+0.64%)

As of 04:21 PM Eastern

Compare

BTMD vs. ELDN, TKNO, HUMA, ZNTL, and AVXL

Should you buy biote stock or one of its competitors? MarketBeat compares biote with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with biote include Eledon Pharmaceuticals (ELDN), Alpha Teknova (TKNO), Humacyte (HUMA), Zentalis Pharmaceuticals (ZNTL), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry.

How does biote compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

biote has a net margin of 8.29% compared to Eledon Pharmaceuticals' net margin of 0.00%. biote's return on equity of -25.72% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
biote	8.29%	-25.72%	15.12%

Eledon Pharmaceuticals currently has a consensus price target of $9.67, suggesting a potential upside of 168.52%. biote has a consensus price target of $2.75, suggesting a potential upside of 16.53%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, biote had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 3 mentions for biote and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.23 beat biote's score of 0.38 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
biote	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, biote has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

biote has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
biote	$192.22M	0.46	$27.05M	$0.44	5.36

Summary

biote beats Eledon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does biote compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Alpha Teknova has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, biote has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

biote has a net margin of 8.29% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
biote	8.29%	-25.72%	15.12%

biote has higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	7.18	-$17.26M	-$0.32	N/A
biote	$192.22M	0.46	$27.05M	$0.44	5.36

Alpha Teknova currently has a consensus price target of $8.00, suggesting a potential upside of 47.33%. biote has a consensus price target of $2.75, suggesting a potential upside of 16.53%. Given Alpha Teknova's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alpha Teknova is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, biote had 3 more articles in the media than Alpha Teknova. MarketBeat recorded 3 mentions for biote and 0 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.89 beat biote's score of 0.38 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Teknova	Very Positive
biote	Neutral

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 12.5% of Alpha Teknova shares are owned by company insiders. Comparatively, 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

biote beats Alpha Teknova on 11 of the 17 factors compared between the two stocks.

How does biote compare to Humacyte?

Humacyte (NASDAQ:HUMA) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Humacyte currently has a consensus target price of $6.43, indicating a potential upside of 331.45%. biote has a consensus target price of $2.75, indicating a potential upside of 16.53%. Given Humacyte's stronger consensus rating and higher possible upside, equities analysts clearly believe Humacyte is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, biote had 1 more articles in the media than Humacyte. MarketBeat recorded 3 mentions for biote and 2 mentions for Humacyte. Humacyte's average media sentiment score of 1.04 beat biote's score of 0.38 indicating that Humacyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
biote	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

biote has a net margin of 8.29% compared to Humacyte's net margin of -4,836.06%. biote's return on equity of -25.72% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
biote	8.29%	-25.72%	15.12%

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 3.1% of Humacyte shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

biote has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	162.16	-$40.83M	-$0.57	N/A
biote	$192.22M	0.46	$27.05M	$0.44	5.36

Humacyte has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market. Comparatively, biote has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

Summary

biote beats Humacyte on 9 of the 16 factors compared between the two stocks.

How does biote compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

biote has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.09	-$137.06M	-$1.73	N/A
biote	$192.22M	0.46	$27.05M	$0.44	5.36

biote has a net margin of 8.29% compared to Zentalis Pharmaceuticals' net margin of 0.00%. biote's return on equity of -25.72% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
biote	8.29%	-25.72%	15.12%

21.7% of biote shares are owned by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zentalis Pharmaceuticals currently has a consensus target price of $5.83, indicating a potential upside of 50.73%. biote has a consensus target price of $2.75, indicating a potential upside of 16.53%. Given Zentalis Pharmaceuticals' higher possible upside, equities analysts clearly believe Zentalis Pharmaceuticals is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 3 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 0.47 beat biote's score of 0.38 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
biote	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zentalis Pharmaceuticals has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, biote has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

Summary

biote beats Zentalis Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does biote compare to Anavex Life Sciences?

biote (NASDAQ:BTMD) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

biote presently has a consensus price target of $2.75, indicating a potential upside of 16.53%. Anavex Life Sciences has a consensus price target of $21.33, indicating a potential upside of 656.50%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

21.7% of biote shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 11.4% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, biote had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for biote and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.93 beat biote's score of 0.38 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
biote	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

biote has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.46	$27.05M	$0.44	5.36
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

biote has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

biote has a net margin of 8.29% compared to Anavex Life Sciences' net margin of 0.00%. biote's return on equity of -25.72% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Summary

biote beats Anavex Life Sciences on 10 of the 15 factors compared between the two stocks.

Get biote News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTMD vs. The Competition

Export

Metric	biote	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$88.69M	$8.25B	$6.44B	$12.46B
Dividend Yield	N/A	2.61%	2.69%	5.22%
P/E Ratio	5.36	15.68	23.87	24.36
Price / Sales	0.46	7.13	521.52	117.07
Price / Cash	3.70	17.10	41.27	57.13
Price / Book	-1.69	3.63	9.99	6.73
Net Income	$27.05M	$224.05M	$3.56B	$337.03M
7 Day Performance	15.69%	0.30%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-33.33%	2.90%	28.77%	33.98%

biote Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTMD biote	3.5128 of 5 stars	$2.36 +11.8%	$2.75 +16.5%	-40.6%	$88.69M	$192.22M	5.36	194
ELDN Eledon Pharmaceuticals	2.4686 of 5 stars	$3.54 -6.0%	$9.67 +173.5%	+10.1%	$290.23M	N/A	N/A	10	News Coverage Positive News
TKNO Alpha Teknova	3.1914 of 5 stars	$5.21 -3.1%	$8.00 +53.7%	-10.8%	$289.52M	$40.52M	N/A	240	Positive News High Trading Volume
HUMA Humacyte	4.0759 of 5 stars	$1.41 -3.1%	$6.43 +357.5%	-46.2%	$288.62M	$2.04M	N/A	150	Analyst Forecast Gap Down
ZNTL Zentalis Pharmaceuticals	2.8449 of 5 stars	$3.94 -1.1%	$5.83 +48.2%	+173.5%	$283.32M	N/A	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTMD) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

biote (BTMD) Competitors

BTMD vs. ELDN, TKNO, HUMA, ZNTL, and AVXL

How does biote compare to Eledon Pharmaceuticals?

Summary

How does biote compare to Alpha Teknova?

Summary

How does biote compare to Humacyte?

Summary

How does biote compare to Zentalis Pharmaceuticals?

Summary

How does biote compare to Anavex Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD vs. The Competition

biote Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

biote (BTMD) Competitors

BTMD vs. ELDN, TKNO, HUMA, ZNTL, and AVXL

How does biote compare to Eledon Pharmaceuticals?

Is ELDN or BTMD more profitable?

Do analysts rate ELDN or BTMD?

Does the media refer more to ELDN or BTMD?

Do insiders and institutionals have more ownership in ELDN or BTMD?

Which has more risk & volatility, ELDN or BTMD?

Which has higher earnings & valuation, ELDN or BTMD?

Summary

How does biote compare to Alpha Teknova?

Which has more volatility and risk, TKNO or BTMD?

Is TKNO or BTMD more profitable?

Which has stronger earnings and valuation, TKNO or BTMD?

Do analysts recommend TKNO or BTMD?

Does the media refer more to TKNO or BTMD?

Do institutionals and insiders have more ownership in TKNO or BTMD?

Summary

How does biote compare to Humacyte?

Do analysts rate HUMA or BTMD?

Does the media favor HUMA or BTMD?

Is HUMA or BTMD more profitable?

Do insiders and institutionals have more ownership in HUMA or BTMD?

Which has higher valuation and earnings, HUMA or BTMD?

Which has more risk & volatility, HUMA or BTMD?

Summary

How does biote compare to Zentalis Pharmaceuticals?

Which has higher valuation and earnings, ZNTL or BTMD?

Is ZNTL or BTMD more profitable?

Do insiders and institutionals have more ownership in ZNTL or BTMD?

Do analysts rate ZNTL or BTMD?

Does the media favor ZNTL or BTMD?

Which has more risk & volatility, ZNTL or BTMD?

Summary

How does biote compare to Anavex Life Sciences?

Do analysts recommend BTMD or AVXL?

Do insiders and institutionals believe in BTMD or AVXL?

Does the media prefer BTMD or AVXL?

Which has higher valuation & earnings, BTMD or AVXL?

Which has more volatility and risk, BTMD or AVXL?

Is BTMD or AVXL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD vs. The Competition

biote Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools